Melanoma (Skin) Clinical Trial
Official title:
Skin Self-Examination for Early Detection of Melanoma: Intervention and Consequence
RATIONALE: An educational program may be effective in increasing monthly skin
self-examinations to detect melanoma in healthy participants.
PURPOSE: This randomized clinical trial is studying how well an educational program works in
increasing monthly skin self-examinations to detect melanoma in healthy participants.
OBJECTIVES:
- Determine the incidence of monthly thorough skin self-examinations (TSE) for early
detection of melanoma in healthy participants who are under routine care by their
primary care physician.
- Determine the impact of the intervention package and the resulting change in TSE
performance, in terms of visits to healthcare providers for skin problems, in these
participants.
- Evaluate the efficacy of this intervention package in improving performance of TSE in
these participants.
- Estimate potential effect of this intervention on health care resource use.
OUTLINE: This is a controlled, randomized study.
Two weeks prior to their appointment with their physician, participants undergo a baseline
assessment. During the appointment, participants are randomized to 1 of 2 intervention arms.
- Arm I (control): Participants receive written educational materials and watch a video
on healthy dietary habits during their appointment. They receive nutrition tip sheets,
including information related to reducing fat, saturated fat, and cholesterol in the
diet, at 2 and 6 months after their initial appointment. Participants also undergo
telephone assessments at 2, 6, and 12 months after their initial appointment.
- Arm II (skin self-examinations): Participants undergo a 10- to 15-minute face-to-face
counseling session with the study intervention specialist and receive training in
thorough skin self-examination (TSE) directly after their appointment. They also
receive written educational materials and watch a 25-minute video designed to motivate
and teach them to do TSE. Two weeks later, participants receive a follow-up call from
the same study intervention specialist. Participants receive tailored feedback at 2 and
6 months and a motivational postcard at 4 months after their initial appointment.
Participants also undergo telephone assessments as in arm I.
Participating physicians seeing participants in both arms attend a 60-minute educational
session regarding skin cancer detection, prevention, identification, and triage,
supplemented by written materials. They are also trained and prompted to deliver a 30-second
message emphasizing the desirability of performing monthly TSE during their appointment with
participants.
After completion of the study intervention, participants are offered the educational
materials of the intervention arm to which they were not randomized.
PROJECTED ACCRUAL: A total of 1,135 participants will be accrued for this study.
;
Allocation: Randomized, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04062032 -
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
|
Phase 2 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Completed |
NCT00962845 -
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT00324623 -
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
|
Phase 1 | |
Completed |
NCT00104845 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 1 | |
Completed |
NCT00096382 -
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00072085 -
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00072124 -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
|
Phase 3 | |
Completed |
NCT00089193 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT00039234 -
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
|
Phase 3 | |
Completed |
NCT00049010 -
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
|
N/A | |
Completed |
NCT00042783 -
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00006385 -
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
Completed |
NCT00020358 -
Vaccine Therapy in Treating Patients With Melanoma
|
Phase 2 | |
Completed |
NCT00005610 -
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 |